Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
The focus is to derive insights, identify trends, and visualize data in a meaningful way. Abhishek123sain / data-analysis-and-insights Public Notifications You must be signed in to change notification ...
Abstract No abstract received.Dedication: Dedicated to Professor Ivan Todorov on the occasion of his 70th birthday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback